STOCK TITAN

Vanguard reports 8.27M Quest Diagnostics shares (NYSE: DGX) stake

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Vanguard Capital Management filed a Schedule 13G reporting beneficial ownership of 8,274,567 shares of Quest Diagnostics Inc Common Stock. The filing states this equals 7.53% of the class as of 03/31/2026, with 1,128,895 shares for which Vanguard has sole voting power and 8,274,567 shares for which it has sole dispositive power. The filing lists affiliated Vanguard entities and notes holdings include securities held for Vanguard funds and managed accounts.

Positive

  • None.

Negative

  • None.

Insights

Large passive stake disclosed: 8,274,567 shares (7.53%).

Vanguard Capital Management reports a non‑operatorial, beneficial holding representing 7.53% of Quest Diagnostics common stock as of 03/31/2026. The filing attributes voting and dispositive powers across Vanguard affiliates and managed funds.

Because Schedule 13G filings are generally passive disclosures, this is a snapshot of ownership structure; subsequent filings could show changes in percent or voting intent.

Shares beneficially owned 8,274,567 shares Beneficial ownership reported as of 03/31/2026
Percent of class 7.53% Percent of outstanding common stock as reported
Sole voting power 1,128,895 shares Number with sole power to vote
Sole dispositive power 8,274,567 shares Number with sole power to dispose
CUSIP 74834L100 Quest Diagnostics common stock identifier
Schedule 13G regulatory
"Vanguard Capital Management filed a Schedule 13G reporting beneficial ownership"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
Beneficially owned regulatory
"reflects the securities beneficially owned, or deemed to be beneficially owned"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Sole dispositive power regulatory
"Sole power to dispose or to direct the disposition of: 8274567"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
Investment Company Act regulatory
"investment companies registered under the Investment Company Act of 1940"
The Investment Company Act is a law that sets rules for businesses whose main activity is managing and selling pooled money, such as mutual funds and other investment funds. It matters to investors because it requires clear reporting, limits managers from putting their own interests ahead of clients, and mandates safekeeping and oversight of assets—similar to safety inspections and traffic rules that help keep shared vehicles reliable and trustworthy.





74834L100

(CUSIP Number)
03/31/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Capital Management LLC and the following affiliates of Vanguard Capital Management LLC or business divisions of such affiliates: Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC and Vanguard Investments Australia Ltd. This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Capital Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power. This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Capital Management LLC, or business divisions of such subsidiaries, whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release.


SCHEDULE 13G



Vanguard Capital Management
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:04/30/2026

FAQ

What stake does Vanguard Capital Management report in Quest Diagnostics (DGX)?

Vanguard Capital Management reports beneficial ownership of 8,274,567 shares, equal to 7.53% of Quest Diagnostics common stock as of 03/31/2026. The filing lists both voting and dispositive power figures for Vanguard affiliates.

How many shares does Vanguard have sole voting power over in DGX?

The filing states Vanguard has sole voting power over 1,128,895 shares. It also reports sole dispositive power over 8,274,567 shares, per the Schedule 13G disclosure dated 03/31/2026.

Does the Schedule 13G identify which Vanguard entities hold the DGX shares?

Yes. The filing names Vanguard Capital Management LLC and affiliates including Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC, and Vanguard Investments Australia Ltd as relevant entities exercising power over the shares.

Is Vanguard acting as an active investor in Quest Diagnostics per this filing?

The Schedule 13G format indicates a passive investor disclosure. The filing lists beneficial ownership and powers but does not state active intent to influence management or control; it reports holdings across Vanguard funds and managed accounts.

What CUSIP and class are reported for Quest Diagnostics in this filing?

The filing lists the security as Common Stock with CUSIP 74834L100 for Quest Diagnostics Inc. The ownership figures reported relate specifically to that class of common stock.